Abstract

The continuance of M&A as dominating the deal making field was 'the buzz' at this year's JPMorgan Annual Healthcare Conference, particularly with biotech as the acquisition target. With the forecasted consolidation of biotech happening, and looking as if it will continue to happen in 2006, a question may be posed as to the likely status of emerging speciality companies and their remaining independence.

Copyright: © IQVIA 2018